NCT05191381 (IMECOV19) is a clinical trial of Application of exosomes in a whole blood assay in COVID-19, sponsored by University of Ulm.

Who is sponsoring NCT05191381?

NCT05191381 is sponsored by University of Ulm.

What drugs are being tested in NCT05191381?

Interventions in NCT05191381: Application of exosomes in a whole blood assay.

What condition does NCT05191381 study?

NCT05191381 studies COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis.

Is NCT05191381 still recruiting?

NCT05191381 is currently recruiting now. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT05191381: IMECOV19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immune Modulation by Exosomes in COVID-19

Recruiting now Last updated 17 January 2024

What this trial tests

trial testing Application of exosomes in a whole blood assay in COVID-19 in 40 participants. Currently enrolling.

Timeline

22 December 2021

Primary endpoint
31 July 2025

31 December 2026

Quick facts

Lead sponsor	University of Ulm
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	40
Start date	22 December 2021
Primary completion	31 July 2025
Estimated completion	31 December 2026
Sites	1 location across Germany

Drugs / interventions tested

Application of exosomes in a whole blood assay — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Critical Illness — all drugs for Critical Illness →
Hypercytokinemia — all drugs for Hypercytokinemia →
Lung Fibrosis — all drugs for Lung Fibrosis →

Sponsor

University of Ulm

Who can join

Adults 18 to 90, any sex, with COVID-19 or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The roles of extracellular vesicles in the immune system.
Buzas EI. · · 2023 · cited 811× · PMID 35927511 · DOI 10.1038/s41577-022-00763-8
Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z
Extracellular vesicles as bioactive nanotherapeutics: An emerging paradigm for regenerative medicine.
Li M, Fang F, Sun M, Zhang Y, et al · · 2022 · cited 84× · PMID 35836815 · DOI 10.7150/thno.72812
Exosome and virus infection.
Peng Y, Yang Y, Li Y, Shi T, et al · · 2023 · cited 42× · PMID 37063897 · DOI 10.3389/fimmu.2023.1154217
Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.
Zhang E, Phan P, Zhao Z. · · 2023 · cited 27× · PMID 37250173 · DOI 10.1016/j.apsb.2022.08.020
Mesenchymal Stem Cell-Derived Extracellular Vesicles in the Management of COVID19-Associated Lung Injury: A Review on Publications, Clinical Trials and Patent Landscape.
Krishnan A, Muthusamy S, Fernandez FB, Kasoju N. · · 2022 · cited 22× · PMID 35384633 · DOI 10.1007/s13770-022-00441-9
Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M, Bayati P, Mojtabavi N. · · 2024 · cited 18× · PMID 38886859 · DOI 10.1186/s13287-024-03782-5
Extracellular Vesicle-Based Therapeutics in Neurological Disorders.
Yuan Y, Sun J, You T, Shen W, et al · · 2022 · cited 15× · PMID 36559145 · DOI 10.3390/pharmaceutics14122652

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Ulm trials

Trials by the same sponsor.

NCT07436195 — Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA · recruiting
NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
NCT06877143 — Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis · NA · recruiting
NCT06280079 — Ultra-high-caloric, Fatty Diet in ALS · NA · recruiting
NCT06627348 — Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05191381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Ulm
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05191381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing